Vanessa Buatois
Discovery Program Leader Light Chain Bioscience / Novimmune
Seminars
Thursday 9th July 2026
Tumour-Selective Activation of TNFR via Bispecific Antibody Combination
5:00 pm
- Our proprietary k/l bsAb platform allows production of a combination of bsAbs in the same cell and their subsequent purification
- Exploring how bsAbs have been developed to selectively activate TNFR in a tumourassociated antigen (TAA)-dependent manner
- This report investigates whether a combination of bsAbs, pairing TNFR and TAA targeting arms, can further enhance TNFR clustering and activation in the tumour microenvironment
